(Sharecast News) - UK pharmaceutical company GSK raised annual forecasts after better-than-expected second-quarter results, driven by a strong performance from its cancer and HIV treatments.


Second-quarter sales rose 13% to £7.88bn beating analysts' average forecasts of £7.51bn in a company-compiled consensus.

The company now expects 2024 core...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE